TY - JOUR
T1 - Advanced nanovaccines based on engineering nanomaterials for accurately enhanced cancer immunotherapy
AU - Wang, Dandan
AU - Gu, Wenxing
AU - Chen, Weiliang
AU - Zhou, Jin
AU - Yu, Le
AU - Kook Kim, Byung
AU - Zhang, Xuenong
AU - Seung Kim, Jong
N1 - Funding Information:
This work was supported by the Natural Science Foundation of China (Granted numbers 81773183 and 21705120 ), the Technology Support Project of Shandong Province Higher Educational Youth Innovation (Granted numbers 2019KJM008). Appreciated for the grants from Royal College of Surgeons in Ireland (RCSI) StAR 2021 programma (R21393A07) and the China Scholarship Council (CSC, granted, No. [2021]395). Greatly appreciated for the support of Prof. Sally-Ann Cryan (RCSI). This work was also supported by the National Research Foundation of Korea (CRI Project Nos. 2018R1A3B1052702 and 2019M3E5D1A01068998, J.S.K.).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - In recent years, nanovaccine based on nanomaterials emerging as an advanced nanotechnology has drawn more attention for accurately enhancing anti-tumor immunotherapy. Nanovaccine loaded with antigen and immunopotentiator could stimulate antigen presenting cells (APCs) to release signals of co-stimulatory cytokines and reinvigorate the immune-killing T cell to alleviate tumor progression. The amplification of co-stimulatory markers has the potential to enhance the sensitivity of APCs towards tumor neoantigens. Furthermore, positive regulation via nanovaccine of antigen-dependent APCs with a “self-promoting” effect with more recruits of immune-killing T cells could contribute to potentiating the presentation and processing of antigen, finally improving the efficacy of immunotherapy. Of note, if the intracellular and exocellular delivery of antigen could be effectively manipulated, the well-designed nanovaccine will provide a platform for clinical therapeutic practice. In this review, we summarize the development, technical advantages and challenges of nanovaccine in the multi-stage delivery process for immune-guided therapeutic efficacy.
AB - In recent years, nanovaccine based on nanomaterials emerging as an advanced nanotechnology has drawn more attention for accurately enhancing anti-tumor immunotherapy. Nanovaccine loaded with antigen and immunopotentiator could stimulate antigen presenting cells (APCs) to release signals of co-stimulatory cytokines and reinvigorate the immune-killing T cell to alleviate tumor progression. The amplification of co-stimulatory markers has the potential to enhance the sensitivity of APCs towards tumor neoantigens. Furthermore, positive regulation via nanovaccine of antigen-dependent APCs with a “self-promoting” effect with more recruits of immune-killing T cells could contribute to potentiating the presentation and processing of antigen, finally improving the efficacy of immunotherapy. Of note, if the intracellular and exocellular delivery of antigen could be effectively manipulated, the well-designed nanovaccine will provide a platform for clinical therapeutic practice. In this review, we summarize the development, technical advantages and challenges of nanovaccine in the multi-stage delivery process for immune-guided therapeutic efficacy.
KW - Antigen delivery
KW - Antigen presentation processing
KW - Cancer immunotherapy
KW - Dendritic cells-targeting
KW - Immune activations
KW - Nanovaccine
UR - http://www.scopus.com/inward/record.url?scp=85136567206&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2022.214788
DO - 10.1016/j.ccr.2022.214788
M3 - Review article
AN - SCOPUS:85136567206
SN - 0010-8545
VL - 472
JO - Coordination Chemistry Reviews
JF - Coordination Chemistry Reviews
M1 - 214788
ER -
